User:Mr. Ibrahem/Vedolizumab

Vedolizumab, sold under the brand name Entyvio, is a medication used to treat moderate to severe ulcerative colitis or Crohn's disease that has not responded to other treatments. It is given by gradual injection into a vein. Resistance to the medication may develop.

Common side effects may include joint pain, nausea, fever, and sinusitis. Other side effects may include anaphylaxis, infections, and progressive multifocal leukoencephalopathy. It is a monoclonal antibody which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1) resulting in decreased inflammation.

Vedolizumab was approved for medical use in Europe and the United States in 2014. In the United Kingdom it costs the NHS about £2,050 a dose. In the United States this amount costs about 6,700 USD as of 2020 or about 40,400 USD per year. In Canada it is about 21,500 CAD a year as of 2016.